Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.

Anetsberger, Aida; Blobner, Manfred; Haller, Bernhard; Schmid, Sebastian; Umgelter, Katrin; Hager, Theresa; Langgartner, Clemens; Kochs, Eberhard F; Laugwitz, Karl-Ludwig; Jungwirth, Bettina; Bernlochner, Isabell

doi:10.1160/TH16-10-0804

2017

Back
Back to start of result list
Permanent link for displayed object

Title:: Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
Document type:: Journal Article
Author(s):: Anetsberger, Aida; Blobner, Manfred; Haller, Bernhard; Schmid, Sebastian; Umgelter, Katrin; Hager, Theresa; Langgartner, Clemens; Kochs, Eberhard F; Laugwitz, Karl-Ludwig; Jungwirth, Bettina; Bernlochner, Isabell
Abstract:: This study evaluates whether immature platelets (IPF) determined in the post anesthesia care unit (PACU) can predict major adverse cardiovascular events (MACE) or other thromboembolic events after intermediate and high-risk surgery. IPF are increased in patients with acute coronary syndrome and recently gained interest as novel biomarker for risk stratification. In this prospective observational trial 732 patients undergoing intermediate or high-risk non-cardiac surgery were enrolled (NCT02097602). IPF was measured preoperatively and postoperatively in the PACU. Primary outcome was a composite endpoint defined as MACE, deep vein thrombosis or pulmonary embolism during hospital stay (modMACE). A cut off for IPF identifying a threshold between a low and high risk for modMACE was calculated by log-rank optimization. A multivariate Cox regression was calculated in a forward stepwise manner to assess the relation between this IPF cut off and modMACE as well as other established risk factors (inclusion if p<0.05). Preoperatively, there were no differences in IPF between patients with and without modMACE (3.1 % [2.2 % - 4.7 %](median [interquartile range]) vs. 2.8 % [1.9 % - 4.3 %]. Patients with modMACE (28 of 730 patients; 3.8 %) had higher IPF values in the PACU compared to patients without modMACE (3.6 % [2.6-6 %] vs. 2.9 % [2-4.4 %]; p=0.011). The optimal cut off of IPF > 5.4 % was associated with an increased risk for modMACE after adjustment for covariates (hazard ratio: 2.528; 95 % confidence interval: 1.156 to 5.528, p=0.02). In conclusion, IPF is an independent predictor of modMACE after surgery and might improve risk stratification of surgical patients.
Journal title abbreviation:: Thromb Haemost
Year:: 2017
Journal volume:: 117
Journal issue:: 10
Pages contribution:: 1887-1895
Language:: eng
Fulltext / DOI:: doi:10.1160/TH16-10-0804
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/28796275
Print-ISSN:: 0340-6245
TUM Institution:: I. Medizinische Klinik und Poliklinik (Kardiologie); Institut für Medizinische Statistik und Epidemiologie; Klinik für Anästhesiologie (DHM)
BibTeX